NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 305 filers reported holding NOVOCURE LTD in Q3 2022. The put-call ratio across all filers is 1.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $245,869 | -4.7% | 3,352 | -1.2% | 0.00% | 0.0% |
| Q3 2022 | $258,000 | +20.0% | 3,394 | +9.6% | 0.00% | 0.0% |
| Q2 2022 | $215,000 | -14.0% | 3,096 | +2.7% | 0.00% | 0.0% |
| Q1 2022 | $250,000 | -12.0% | 3,016 | -20.3% | 0.00% | 0.0% |
| Q4 2021 | $284,000 | -34.4% | 3,782 | +1.4% | 0.00% | 0.0% |
| Q3 2021 | $433,000 | -43.9% | 3,729 | +7.2% | 0.00% | -50.0% |
| Q2 2021 | $772,000 | +259.1% | 3,479 | +114.1% | 0.00% | +100.0% |
| Q1 2021 | $215,000 | -68.7% | 1,625 | -59.1% | 0.00% | -50.0% |
| Q4 2020 | $687,000 | +175.9% | 3,972 | +7.3% | 0.00% | +100.0% |
| Q1 2020 | $249,000 | -40.3% | 3,702 | -25.2% | 0.00% | -50.0% |
| Q4 2019 | $417,000 | +19.8% | 4,952 | +6.4% | 0.00% | 0.0% |
| Q3 2019 | $348,000 | -57.0% | 4,652 | -72.3% | 0.00% | -50.0% |
| Q1 2019 | $809,000 | -49.7% | 16,800 | -45.3% | 0.00% | -50.0% |
| Q3 2018 | $1,609,000 | – | 30,700 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $77,833,000 | 15.51% |
| HARTLINE INVESTMENT CORP/ | 302,194 | $67,033,000 | 8.47% |
| Darsana Capital Partners LP | 700,000 | $155,274,000 | 4.42% |
| MORGAN JESS S & CO INC | 23,775 | $5,274,000 | 3.47% |
| Soleus Capital Management, L.P. | 98,975 | $21,955,000 | 3.38% |
| Montanaro Asset Management Ltd | 116,650 | $25,875,000 | 3.26% |
| Taylor Frigon Capital Management LLC | 31,035 | $6,884,000 | 2.15% |
| Rhenman & Partners Asset Management AB | 120,000 | $26,618,000 | 1.81% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $2,218,000 | 1.33% |
| Derbend Asset Management | 5,789 | $1,284,000 | 1.20% |